# RheOx Registry Study in Europe

> **NCT04182841** · NA · UNKNOWN · sponsor: **Gala Therapeutics, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Bronchitis
- COPD

## Interventions

- **DEVICE:** RheOx

## Key facts

- **NCT ID:** NCT04182841
- **Lead sponsor:** Gala Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-09
- **Primary completion:** 2024-12-15
- **Final completion:** 2025-12-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04182841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04182841, "RheOx Registry Study in Europe". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04182841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*